We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sequencing-Based Testing Sector Already Highly Competitive

By LabMedica International staff writers
Posted on 22 Mar 2015
Print article
As next-generation sequencing (NGS) reaches the clinical laboratory, a new analysis by Kalorama Information (New York, NY, USA) finds that small reference laboratories as well as over 50 companies now offer sequencing-based testing through their own CLIA-certified laboratories, some of which offer a wide range of tests.

“These firms and reference laboratories offer next-gen sequencing that they perform and charge for as a service,” said Bruce Carlson, Kalorama publisher. [Tests for presence of or] “Increased risk for breast and colon cancers, childhood epilepsy, renal disorders, prenatal tests, and many others are available now.” The new report, “Next Generation Sequencing Markets 2015,” features detailed information on top market competitors.

The large amounts of sequence date generated by NGS research can be valuable for trying to answer many questions regarding the genome and disease, but initially cannot be used by clinicians in making treatment decisions. Kalorama notes that diagnostic companies have realized the importance of more targeted approaches focusing on gene mutations with known clinical utility. In addition, sequencing platforms have traditionally been expensive, and using these instruments to test samples has been complex – with requirements for sample preparation, sequencing, and results analysis and interpretation. This has made it difficult to follow the traditional in vitro diagnostic (IVD) approach of developing kits that can be sold to clinical laboratories that would perform the tests. As a result, diagnostic sequencing has generally been performed by clinical laboratories or by companies that establish their own CLIA-certified laboratory.

Kalorama’s report provides details on NGS test offerings of each company as well as detailed tables indicating activities of competitors. The report breaks out system, consumable, and service segments, and provides information on brand ownership and regional installed base of sequencers.

Related Links:

Kalorama Information
Next Generation Sequencing Markets 2015, report


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.